Infinity Pharmaceuticals To Present At BIO CEO & Investor Conference
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. MARIO-1, a Phase 1/1b study in approximately 200 patients with advanced solid tumors is ongoing, and Infinity plans to initiate MARIO-275, a global, randomized study evaluating the addition of IPI-549 to nivolumab in cisplatin-refractory, I/O naïve urothelial cancer patients, in the first half of 2019. For more information on Infinity, please refer to Infinity's website at www.infi.com.
212-362-1200 or Stephanie@sternir.com